Literature DB >> 8388903

Depressed neutrophil superoxide production in human immunodeficiency virus infection.

D L Pitrak1, P M Bak, P DeMarais, R M Novak, B R Andersen.   

Abstract

Neutrophil (PMNL) superoxide (O2-) production was evaluated in 71 patients with human immunodeficiency virus (HIV) infection at different stages of disease. In vitro O2- production was significantly depressed for PMNL isolated from HIV-positive patients compared with control PMNL at rest and after stimulation. The degree of impairment of O2- production was more pronounced for patients with lower absolute CD4+ lymphocyte counts. Antiretroviral therapy with zidovudine was also associated with impaired O2- production, but this may reflect a longer duration of disease for treated patients. Zidovudine had no direct inhibitory effect on O2- production by control PMNL in vitro, and serial measurements of O2- production by PMNL from patients before and after initiation of zidovudine did not demonstrate an in vivo inhibitory effect. Impaired PMNL oxidative metabolism in HIV infection may contribute to the increased risk of serious bacterial infections, certain opportunistic infections, and perhaps the pathogenesis of HIV infection itself.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8388903     DOI: 10.1093/infdis/167.6.1406

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  23 in total

1.  Dysregulation in IL-12 secretion by neutrophils from HIV-infected patients.

Authors:  A Vecchiarelli; C Monari; B Palazzetti; F Bistoni; A Casadevall
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

2.  Impaired interleukin-8-induced degranulation of polymorphonuclear neutrophils from human immunodeficiency virus type 1-infected individuals.

Authors:  S Meddows-Taylor; D J Martin; C T Tiemessen
Journal:  Clin Diagn Lab Immunol       Date:  1999-05

3.  Impaired phagocytosis among patients infected by the human immunodeficiency virus: implication for a role of highly active anti-retroviral therapy.

Authors:  C Michailidis; G Giannopoulos; V Vigklis; K Armenis; A Tsakris; P Gargalianos
Journal:  Clin Exp Immunol       Date:  2012-03       Impact factor: 4.330

4.  HIV-1-infected peripheral blood mononuclear cells enhance neutrophil survival and HLA-DR expression via increased production of GM-CSF: implications for HIV-1 infection.

Authors:  Jun Fu; Beverly E Sha; Larry L Thomas
Journal:  J Acquir Immune Defic Syndr       Date:  2011-01-01       Impact factor: 3.731

5.  Neutrophil Vaccination Dynamics and Their Capacity To Mediate B Cell Help in Rhesus Macaques.

Authors:  Thomas Musich; Mohammad Arif Rahman; Venkatramanan Mohanram; Leia Miller-Novak; Thorsten Demberg; David J Venzon; Barbara K Felber; Genoveffa Franchini; George N Pavlakis; Marjorie Robert-Guroff
Journal:  J Immunol       Date:  2018-09-14       Impact factor: 5.422

6.  Granulocyte colony-stimulating factor administration to HIV-infected subjects augments reduced leukotriene synthesis and anticryptococcal activity in neutrophils.

Authors:  M J Coffey; S M Phare; S George; M Peters-Golden; P H Kazanjian
Journal:  J Clin Invest       Date:  1998-08-15       Impact factor: 14.808

7.  Impaired macrophage phagocytosis of apoptotic neutrophils in patients with human immunodeficiency virus type 1 infection.

Authors:  Donato Torre; Luisa Gennero; F M Baccino; Filippo Speranza; Gilberto Biondi; Agostino Pugliese
Journal:  Clin Diagn Lab Immunol       Date:  2002-09

Review 8.  Neutropenia during HIV infection: adverse consequences and remedies.

Authors:  Xin Shi; Matthew D Sims; Michel M Hanna; Ming Xie; Peter G Gulick; Yong-Hui Zheng; Marc D Basson; Ping Zhang
Journal:  Int Rev Immunol       Date:  2014-03-21       Impact factor: 5.311

Review 9.  Th17 cytokines and the gut mucosal barrier.

Authors:  Christoph Blaschitz; Manuela Raffatellu
Journal:  J Clin Immunol       Date:  2010-02-02       Impact factor: 8.317

Review 10.  Human Immunodeficiency Virus Infection and Host Defense in the Lungs.

Authors:  Tysheena P Charles; Judd E Shellito
Journal:  Semin Respir Crit Care Med       Date:  2016-03-14       Impact factor: 3.119

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.